Analysts' ratings for Agilon Health AGL over the last quarter vary from bullish to bearish, as provided by 10 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 1 | 5 | 2 | 2 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 2 | 1 | 2 |
| 3M Ago | 0 | 0 | 1 | 1 | 0 |
Analysts have set 12-month price targets for Agilon Health, revealing an average target of $2.58, a high estimate of $4.00, and a low estimate of $1.75. This current average represents a 51.87% decrease from the previous average price target of $5.36.
Breaking Down Analyst Ratings: A Detailed Examination
The standing of Agilon Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Tao Qiu | Macquarie | Announces | Neutral | $3.00 | - |
| Lance Wilkes | Bernstein | Announces | Market Perform | $2.50 | - |
| Sean Dodge | RBC Capital | Maintains | Outperform | $3.00 | $3.00 |
| Daniel Grosslight | Citigroup | Lowers | Sell | $1.75 | $2.50 |
| Craig Jones | Stifel | Lowers | Hold | $2.00 | $7.00 |
| Gary Taylor | TD Cowen | Lowers | Hold | $2.00 | $6.00 |
| Andrew Mok | Barclays | Lowers | Underweight | $2.00 | $5.00 |
| Daniel Grosslight | Citigroup | Lowers | Sell | $2.50 | $7.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | In-Line | $4.00 | $7.00 |
| Kevin Fischbeck | B of A Securities | Announces | Underperform | $3.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Agilon Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Agilon Health compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Agilon Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Agilon Health's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Agilon Health analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Agilon Health's Background
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
Agilon Health's Economic Impact: An Analysis
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Agilon Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.63% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -8.11%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Agilon Health's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -18.8%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Agilon Health's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.53%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Agilon Health's debt-to-equity ratio is below the industry average at 0.08, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
